Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999747 · ClinicalTrials.gov registry record · Phase 3
A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease
A Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
- 12
- Study locations
NCT05999747: Completed Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery, sponsored by Astellas Pharma Global Development.
NCT05999747 is a Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 95 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05999747, a Phase 3 study of Intraoperative Ureter Visualization and Abdominolpelvic Surgery, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
- 12
- Study locations
Study Summary
The ureter is the tube that carries urine from the kidneys to the bladder. It is difficult for surgeons to see the ureter during abdominal surgery. This could lead to injuring the ureter which, although rare, could be serious. This study is about a potential new medical dye, called ASP5354. This dye is injected into the person at the start of surgery and is detected in the ureter. This is done by an imaging machine which has an option called near infrared fluorescence, or NIR-F. Together they show live images of specific parts of the body. In this study, ASP5354 is used with an imaging machine with a NIR-F option to show live images of the ureter during surgery. People with kidneys that work properly and those with kidney problems can take part in this study. The main goal of the study is to find out how clearly the ureter can be seen with ASP5354 during surgery in people whose kidneys work properly or who have mild kidney problems. To do this, the surgeons will inject ASP5354 into the person having surgery. Then, the surgeons will compare images of the ureter with an imaging machine using normal white light and with the NIR-F option. Imaging using normal white light is the standard way surgeons see the ureter during surgery. People 18 years or older, with or without kidney disease, who were going to have certain abdominal surgeries may be able to take part. Everyone taking part will receive ASP5354 during surgery, but how the imaging is done will depend on which group they are in. Before surgery, the people whose kidneys work properly or who have mild kidney problems will be assigned into 1 of 2 groups by chance alone. Images of the ureter will be checked in 1 group using normal white light and the other group using normal white light and NIR-F. People with more severe kidney problems will not be assigned to 1 of 2 groups: all images of the ureter will be checked using normal white light and NIR-F. At the start of surgery, the surgeon will inject ASP5354 into
Primary Outcome
Conspicuity will be scored individually for each illumination mode using the 5-Point Likert Scale, ranging from 1 (None) to 5 (Excellent)
Conditions Studied
Interventions
- DRUG pudexacianinium chloride
Study Locations (12)
California
- Cedars Sinai Medical Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
Florida
- University of South Florida - Tampa
- Cleveland Clinic Florida - Weston
North Carolina
- Duke University Hospital - Durham
- Firsthealth of the Carolinas INC - Pinehurst
Texas
- Baylor College of Medicine - Houston
- Houston Methodist Hospital - Houston
Missouri
- Washington University Center - St Louis
Nevada
- University of Nevada, Las Vegas - Las Vegas
Pennsylvania
- Temple University Hospital - Philadelphia
Washington
- Benaroya Research Institute at VA Mason - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 3 |
What the finished NCT05999747 record still lists
NCT05999747 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Intraoperative Ureter Visualization appearing as the primary indexed condition, and to 1 intervention - of which pudexacianinium chloride is the first listed.
NCT05999747 lists 12 locations in 8 states (California, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT05999747 about?
NCT05999747 is a clinical study titled "A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease". The ureter is the tube that carries urine from the kidneys to the bladder. It is difficult for surgeons to see the ureter during abdominal surgery. This could lead to injuring the ureter which, although rare, could be serious. This study is about a potential new medical dye, called ASP5354. This dy...
What is the current status of trial NCT05999747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2024-03-19. Estimated completion is 2025-10-13.
What conditions does trial NCT05999747 study?
This clinical trial studies the following conditions: Intraoperative Ureter Visualization, Abdominolpelvic Surgery.
What interventions are being tested in trial NCT05999747?
The interventions under investigation include: pudexacianinium chloride (DRUG).
Who is sponsoring clinical trial NCT05999747?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05999747 being conducted?
This trial has 12 study locations across California, Florida, Missouri, Nevada, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intraoperative Ureter Visualization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05999747's enrollment target sits among peer trials
95 1719th of 2000 higher than 282 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI